On July 2, 2020 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that it will host an investor conference call and webcast on Thursday, July 9, 2020 at 9:00 a.m. ET to discuss the Company’s early development pipeline and research (Press release, BeiGene, JUL 2, 2020, View Source/news-releases/news-release-details/beigene-host-investor-conference-call-and-webcast-discuss-0" target="_blank" title="View Source/news-releases/news-release-details/beigene-host-investor-conference-call-and-webcast-discuss-0" rel="nofollow">View Source [SID1234561655]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available for 90 days following the event.